Piper Sandler analyst Joseph Catanzaro maintained a Buy rating on Ocular Therapeutix (OCUL – Research Report) today and set a price target of $10.00. The company’s shares closed yesterday at $5.03.
According to TipRanks, Catanzaro is a 4-star analyst with an average return of 5.9% and a 39.02% success rate. Catanzaro covers the Healthcare sector, focusing on stocks such as Exelixis, Gilead Sciences, and Ocular Therapeutix.
Currently, the analyst consensus on Ocular Therapeutix is a Strong Buy with an average price target of $13.40, implying a 166.40% upside from current levels. In a report released today, Bank of America Securities also initiated coverage with a Buy rating on the stock with a $15.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $7.96 and a one-year low of $2.00. Currently, Ocular Therapeutix has an average volume of 1.34M.
Based on the recent corporate insider activity of 25 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of OCUL in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Ocular Therapeutix (OCUL) Company Description:
Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline include Dextenza, OTX-TP, and OTX-TIC . The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.
Read More on OCUL:
- Ocular Therapeutix Updates Phase 3 SOL Trial Protocol
- Ocular Therapeutix announces FDA agreement to amend SPA for AXPAXLI
- Summer Road raises Ocular Therapeutix stake by $5.0M
- Ocular Therapeutix™ Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
- Ocular Therapeutix 30.8M share Spot Secondary priced at $3.25
